Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitae Rebounds With Reassuring Psoriasis Data

This article was originally published in Scrip

Executive Summary

Two weeks after a stock downturn due to questions about the early closing of Phase IIa enrollment for its first-in-class psoriasis candidate, Vitae Pharmaceuticals Inc. bounced back March 16 with data showing that VTP-43742 offers both efficacy and safety at two doses in patients with moderate to severe plaque psoriasis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel